Pursuant to SEBI Circular dated 31-12-2024 read with BSE circular no 20250102-4 we are submitting herewith our Integrated Filing (Financial) for the Quarter and Year Ended 31-03-2025. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories submitted its audited standalone financial results for Q4 and full year ended March 2025. Revenue from operations fell to Rs 652.77 lakhs in FY25 from Rs 702.96 lakhs in FY24, a decline of about 7%, while Q4 revenue also dropped to Rs 145.14 lakhs from Rs 162.94 lakhs. Profit after tax was nearly flat at Rs 49.66 lakhs versus Rs 48.67 lakhs, with EPS of Rs 1.97 versus Rs 1.93. However, the company reported a sharp swing in operating cash flow, turning negative at Rs (145.37) lakhs for FY25 compared to a positive Rs 103.47 lakhs last year, driven mainly by a large increase in other current assets. The statutory auditor Vora & Associates issued an unqualified opinion on the results.
Mixed signals for shareholders — topline shrank and operating cash flow turned sharply negative, though bottom-line profit stayed steady. The negative operating cash flow despite positive accounting profit is a red flag worth monitoring, while the clean audit opinion provides some comfort.